The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis

Chen, Engeng; Zeng, Zhili; Bai, Bingjun; Zhu, Jing; Song, Zhangfa

doi:10.18632/oncotarget.10964

Cited by 18 publications

(15 citation statements)

References 66 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic and clinicopathological values of CD133 protein and mRNA expression have been indicated in other studies. 3 21 In this hospital-based cohort study, we found that the variant genotypes (AC/CC) of rs2240688 A>C in the miRNA binding site of the stem cell marker gene CD133 was associated with a significantly poorer prognosis for NSCLC patients. The association remained statistically significant (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype) after adjustment for age, sex, smoking status, histopathology type, stage, chemotherapy and radiotherapy.…”

Section: Discussionmentioning

confidence: 76%

“…A meta-analysis showed that NSCLC patients with higher CD133 expression had poor OS only in Asian patients, but not in Caucasian patients. 3 Therefore, high quality and interethnic studies with large samples should be undertaken to confirm the prognostic and clinical value of CD133 .…”

Section: Discussionmentioning

confidence: 99%

“… 2 Approximately 83% of lung cancer patients have non-small cell lung cancer (NSCLC). 3 In addition, despite improvements in technologies and development of multiple treatments including surgery, radiotherapy, chemotherapy and utilisation of other biological agents, the prognosis of NSCLC is very poor due to recurrence and metastasis, with an overall 5-year survival rate <16%. 4–6 Hence, it is necessary to identify biomarkers for the prevention, early diagnosis, monitoring of progression and therapeutic effects of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Polymorphisms of the stem cell marker geneCD133are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients

Zhang

Hou

et al. 2017

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in CD133 (rs2240688A>C, rs10022537T>A, rs7686732C>G, and rs3130C>T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients.DesignRetrospective cohort study.SettingDepartment of General Surgery, in a general hospital, Henan Province, China.ParticipantsNSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion. Those participants who were pregnant or breastfeeding, had a previous history of cancer, had other primary tumours, or who had had primary tumours of the skin and nasopharynx, were excluded from the study.Outcome measuresThe primary endpoint was OS, which was calculated from the date of enrolment until the date of death or date of last follow-up.ResultsThere was a total of 1383 participants, with a median age of 63 years; 726 (52.5%) were male. Compared with thers2240688 AA genotype, the variant AC/CC genotypes were independently associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype). Higher hazard ratios for associations between CD133 rs2240688 polymorphism and OS were observed in patients with adjuvant chemotherapy (HR 1.86, 95% CI 1.52 to 2.26) and radiotherapy for curative intent (HR 1.90, 95% CI 1.55 to 2.33).ConclusionsThe study confirmed the significant association between the SNP rs2240688 A>C of CD133 and OS of NSCLC patients. Larger population-based studies in different ethnic groups are necessary to further validate the role and mechanisms of CD133 in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Polymorphisms of the stem cell marker geneCD133are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients

Zhang

Hou

et al. 2017

BMJ Open

View full text Add to dashboard Cite

show abstract

“…More importantly, CSCs are considered to be involved in chemotherapy/radiotherapy resistance, metastasis, and postoperative recurrence [53, 54]. Some meta-analyses showed that CD133 was a biomarker of putative CSCs in many solid tumors and its positivity may be associated with poor overall survival in nonsmall-cell lung cancer [55], worse prognosis in patients with glioblastoma [20], and reduced overall survival in colorectal cancer [56]. SOX2 expression may be correlated with better overall survival in nonsmall cell lung cancer [21], but worse overall survival in head and neck cancer [57].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of CD133 and SOX2 in Advanced Cancer

Han

Huang

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Background The prognostic value of CD133 and SOX2 expression in advanced cancer remains unclear. This study was first conducted to investigate the association between CD133 or SOX2 positivity and clinical outcomes for advanced cancer patients. Methods Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Trial sequential analysis (TSA) was also performed. Results 13 studies with 1358 cases (CD133) and five studies with 433 cases (SOX2) were identified. CD133 positivity was correlated with worse CSS and OS, but there was no correlation between CD133 positivity and DFS. SOX2 positivity was associated with poor DFS and RFS but was not linked to PFS. Stratified analysis by study source showed that only CD133 positivity can decrease OS for Chinese patients. Stratified analysis by treatment regimens indicated that CD133 positivity was linked to poor OS in patients treated with adjuvant therapy. TSA showed that additional studies were necessary. Conclusions CD133 and SOX2 might be associated with worse prognosis in advanced cancer. More prospective studies are strongly needed. Impact CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients.

show abstract

“…The isolation of lung CSCs provided novel insights into chemoresistance and the high metastatic potential of lung cancer. In several tumors, including lung cancer, CD133 is considered a molecular marker for identifying CSCs, and CD44 and CD133 positive lung cancer cells exhibit the stem‐like properties of tumorigenicity, proliferation, and self‐renewal . Increasing evidence suggested that CD44 + CD133 + CSC populations in NSCLC are responsible for the high resistance to chemotherapeutic drugs and tumor relapse …”

Section: Introductionmentioning

confidence: 99%

MiR‐5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6

Yang

Lin

Wang

et al. 2017

Molecular Carcinogenesis

View full text Add to dashboard Cite

Cisplatin-based chemotherapy is the most commonly used treatment regimen for lung cancer. Cancer stem cells (CSCs) are postulated to be important promoters of drug resistance. We previously found that miR-5100 is overexpressed in lung cancer, but it is unknown whether and how miR-5100 regulates cisplatin resistance. Here, we demonstrated that miR-5100 was significantly up-regulated in CD44 CD133 lung cancer stem cells (LCSCs) compared with non-CSCs. Additionally, over-expression of miR-5100 increased CSC properties, cell growth, and tumor sphere formation in lung cancer cell line A549 or H1299, and that miR-5100 inhibitor significantly increased sensitivity of LCSCs to cisplatin in vitro. Surprisingly, the combination with miR-5100 inhibitor significantly decreased the IC50 of LCSCs to cisplatin. Furthermore, miR-5100 increased CSC properties and cisplatin resistance by inhibiting Rab6, a direct target gene of miR-5100. We demonstrated that miR-5100 overexpression increases the cisplatin resistance of the LCSCs through the mitochondrial apoptosis pathway. In conclusion, our results suggest that miR-5100 increases the cisplatin resistance of the LCSCs by inhibiting the Rab6. This study provides novel insight into the regulation of LCSCs by miRNA.

show abstract

The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis

Cited by 18 publications

References 66 publications

Polymorphisms of the stem cell marker geneCD133are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients

Polymorphisms of the stem cell marker geneCD133are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients

Prognostic Value of CD133 and SOX2 in Advanced Cancer

MiR‐5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6

Contact Info

Product

Resources

About